Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.
Growing research suggests various ways weight loss drugs could have an impact in cancer care.
The Role of Insulin Resistance in Cancer
Insulin resistance is a condition, common in obesity and type 2 diabetes, where the body’s cells do not respond properly to insulin, a hormone that controls blood sugar. This review explains how this metabolic problem is a significant risk factor for several major cancers, including those of the breast, liver, and endometrium. The high levels […]
Obesity-Cancer Link: It’s Worse Than You Think
From WebMD: Cancer deaths are dropping overall, but not the ones linked to obesity. That’s what mounting evidence now shows. A sweeping new report on U.S. cancer trends, published in April, revealed that cancers linked to obesity are becoming more common. Another study, presented in July at the Endocrine Society Annual Meeting in San Francisco, found that deaths from […]
Obesity-associated cancers tripled nationwide over past two decades
SAN FRANCISCO—Cancer deaths linked to obesity have tripled in the United States over the past two decades, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. The study, which examined more than 33,000 deaths from obesity-associated cancers, revealed sharp increases in cancer deaths, especially among […]
Evexomostat Phase 1 Clinical Safety Study in Late-Stage Cancer Patients
2025 Cornelius A phase 1 safety study of evexomostat in patients with late-stage cancer
New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance
SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven (eribulin, Esai). Evexomostat is among the first anti-cancer therapeutics being developed specifically for cancer patients with baseline metabolic dysfunction (obesity, type […]
Prostate Cancer Research Collaboration with Australia Univ. of Technology, Prof. Colleen Nelson, PhD
QUT SDX Collaboration Press Release 07Dec 2021 – Part of an ongoing investigation focused on how obesity and dysregulated metabolic hormones promote prostate cancer progression and metastasis – Studies aim to quantify the ability of SynDevRx MetAP2 inhibitor evexomostat (SDX-7320) to control tumor growth of castration resistant prostate cancers
SynDevRx Announces Research Collaboration with Maine Medical Center Research Institute to Study the Effects of SDX-7320 In Obesity-Accelerated Multiple Myeloma Models
SynDevRx, Inc., a clinical-stage biotechnology company leading the development of treatments for obesity-accelerated cancers, today announced a research collaboration with Maine Medical Center Research Institute’s Michaela Reagan, PhD. The collaboration will study the role of MetAP2 in obesity-accelerated growth and metastatic potential of multiple myeloma – a form of cancer that develops in bone marrow. […]
Obesity, Type 2 Diabetes,and Cancer Risk
Obesity and type 2 diabetes have both been associated with increased cancer risk and are becoming increasingly prevalent. Metabolic abnormalities such as insulin resistance and dyslipidemia are associated with both obesity and type 2 diabetes and have been implicated in the obesity-cancer relationship. Multiple mechanisms have been proposed to link obesity and diabetes with cancer […]
SDX Presents New Oncology Data at 2021 AACR Showing Reversal of Resistance Mechanisms to CDK4/6 Inhibitors
CDK 4/6 inhibitors are an important drug class in 1st line metastatic breast cancer. Unfortunately, resistance inevitably develops and causes treatment failure and the patient’s cancer progresses. Here we show that SDX-7320 overcomes many of the known mechanisms of developed resistance to CDK 4/6 inhibition. 2021 AACR Poster Apr 2021